A cysteine-containing truncated Apo A-I variant associated with HDL deficiency

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 12, 1996, Pages 1416-1423

  Moriyama, Kengo ^a   Sasaki, Jun ^a,d   Takada, Yoichi ^a   Matsunaga, Akira ^a   Fukui, Jun ^b   Albers, John J ^c   Arakawa, Kikuo ^a  

^a School of Medicine   (Japan)

^b Sasebo General Hospital   (Japan)

^c UNIVERSITY OF WASHINGTON   (United States)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

apo A II; apoE; atherosclerosis; genetics; lipoproteins

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL ESTERIFICATION; CLINICAL FEATURE; CORNEA OPACITY; DNA SEQUENCE; FEMALE; FRAMESHIFT MUTATION; GENE DUPLICATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TANGIER DISEASE; XANTHOMA;

EID: 0030482546     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.12.1416     Document Type: Article

References (56)

1. Mahley RW, Innerarity TL, Rall SC, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25:1277-1294.
2. Brewer HB, Fairwell T, LaRue A, Ronan R, Houser A, Bronzen TJ. The amino acid sequence of human apo A-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun. 1978;80:623-630.
3. Bruns GAP, Karathanasis SK, Breslow JL. Human apolipoprotein A-I/C-III complex is located on chromosome 11. Arteriosclerosis. 1984;4:97-102.
4. Karathanasis SK. Apolipoprotein multigene family and tandem organization of human apolipoprotein A-I, C-III and A-IV genes. Proc Natl Acad Sci U S A. 1985;82:6374-6378.
5. Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of the human apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1983;80:6147-6151.
6. Stein O, Stein Y. The removal of cholesterol from Landschutzascites cells by high-density lipoprotein. Biochim Biophys Acta. 1973;326:232-244.
7. Fielding CJ, Shore VG, Fielding P. A protein cofactor of lecithin:cholesterol acyltransferase. Biochem Biophys Res Commun. 1972;46:1493-1498.
8. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol. 1988;4(suppl A):5A-11A.
9. Brunner D, Weisbort J, Meshulam N, Schwartz S, Gross J, Saltz-Rennert H, Altman S, Loebl K. Relationship of serum total cholesterol and high density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty year follow-up of Donolo-Tel Aviv prospective coronary artery disease study. Am J Cardiol. 1987;59:1271-1276.
10. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knobe JD, Jacobs DR Jr, Bangdiwala S, Taylor HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
11. Assmann G, Schulte H, Funke H, von Eckardstein A, Seedorf U. The prospective cardiovascular Munster (PROCAM) study: identification of high-risk individuals for myocardial infarction and the role of high-density lipoprotein. In: Miller NE, ed. High Density Lipoproteins and Atherosclerosis II. Amsterdam, Netherlands: Excerpta Medica. 1989; 826:51-65.
12. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mäntäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki study. Circulation. 1992;85:37-45.
13. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Noffze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary artery disease. N Engl J Med. 1982;306:1513-1519.
14. Karathanasis SK, Ferris E, Haddad EA. DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A. 1987;84:7198-7202.
15. Schaefer EJ, Ordovas JM, Law SW, Ghiselli G, Kashyap ML, Srivastava LS, Heaton WH, Albers JJ, Connor WE, Lindgren FT, Lemeshev Y, Segrest JP, Brewer HB Jr. Familial apolipoprotein A-I and C-III deficiency variant II. J Lipid Res. 1985;26:1089-1101.
16. Ordovas JM, Cassidy DK, Civeira F, Bisgaier C, Schaefer EJ. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem. 1989;264:16339-16342.
17. Hiasa Y, Maeda T, Mori H. Deficiency of apolipoproteins A-I and C-III and severe coronary heart disease. Clin Cardiol. 1986;9: 349-352.
18. Matsunaga T, Hiasa Y, Yanagi H, Maeda T, Hatori N, Yamakawa K, Yamanouchi Y, Tanaka I, Obara T, Hamaguchi H. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1991;88:2793-2797.
19. Funke H, von Eckardstein A, Pritchard PH, Karas M, Albers JJ, Assmann GA. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin:cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest. 1991;87:371-376.
20. Deeb SS, Cheung MC, Reng R, Wolf AC, Stern R, Albers JJ, Knopp RH. A mutation in the human apolipoprotein A-I gene. J Biol Chem. 1991;266:13654-13660.
21. Schmitz G, Lackner KJ. High density lipoprotein deficiency with xanthomas: a defect in apo A-I synthesis? In: Crepaldi G, ed. Atherosclerosis. Amsterdam, the Netherlands; Elsevier Science Publishing Co; 1989;7:399-403.
22. Lackner KJ, Dieplinger H, Nowicka G, Schmitz G. High density lipoprotein deficiency with xanthomas: a defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene. J Clin Invest. 1993;92;2262-2273.
23. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]x causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 1994;93: 223-229.
24. Carlson LA, Philipson B. Fish-eye disease: a new familial condition with massive corneal opacities and dyslipoproteinemia. Lancet. 1979;2;921-924.
25. Breslow JL. Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Vale D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill Publishing Co; 1989:1251-1266.
26. Bekaert ED, Alaupovic P, Knight-Gibson CS, Laux MJ, Pelachyk JM, Norum RA. Characterization of apo A- and apo B-containing lipoprotein particles in a variant of familial apo A-I deficiency with planar xanthoma: the metabolic significance of LP-A-II particles. J Lipid Res. 1991;32:1587-1599.
27. Gustafson A, McConathy WJ, Alaupovic P, Curry MD, Persson B. Identification of lipoprotein families in a variant of human plasma apolipoprotein A deficiency. Scand J Clin Lab Invest. 1977;39: 377-387.
28. Cheung MC, Mendez AJ, Wolf AC, Knopp RH. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux. J Clin Invest. 1993;91:522-529.
29. Assmann G, Schmitz G, Brewer HB Jr. Familial high density lipoprotein deficiency: Tangier disease. In: Scriver CR, Beaudet AL, Sly WS, Vale D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill Publishing Co; 1989:1267-1282.
30. Sasaki J, Arakawa K. Effect of nifedipine on serum lipids, lipoproteins, and apolipoproteins in patients with essential hypertension. Curr Ther Res. 1987;41:845-851.
31. Goto Y, Akanuma Y, Harano Y. Determination by the SRID method of normal values of serum apolipoproteins (A-I, A-II, B, C-II, C-III, and E) in normolipidemic healthy Japanese subjects. J Clin Biochem Nutr. 1986;1:73-88.
32. Matsunaga A, Handa K, Mori T, Moriyama K, Hidaka K, Yuki M, Sasaki J, Arakawa K. Effects of niceritrol on levels of serum lipids, lipoprotein (a), and fibrinogen in patients with primary hypercholesterolemia. Atherosclerosis. 1992;94:241-248.
33. Moriyama K, Sasaki J, Matsunaga A, Arakawa F, Takada Y, Araki K, Kaneko S, Arakawa K. Apolipoprotein E1 Lys-146→Glu with type III hyperlipoproteinemia. Biochim Biophys Acta. 1992;1128:58-64.
34. Koren E, Puchois P, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human plasma apolipoprotein A-I by a non-competitive enzyme-linked immunosorbent assay. Clin Chim Acta. 1985;147:85-95.
35. Takada Y, Sasaki J, Ogata S, Nakanishi T, Ikehara Y, Arakawa K. Isolation and characterization of human apolipoprotein A-I Fukuoka (Glu110→Lys). Biochim Biophys Acta. 1990;1043:169-176.
36. Takada Y, Sasaki J, Seki M, Ogata S, Teranishi Y, Arakawa K. Characterization of a new human apolipoprotein A-I Yame by direct sequencing of polymerase chain reaction-amplified DNA. J Lipid Res. 1991;32:1275-1280.
37. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
38. Gyllensten UB, Erlich HA. Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci U S A. 1988;85:7652-7656.
39. Shoulders CC, Kornblihtt AR, Munro BS, Baralle FE. Gene structure of human apolipoprotein A1. Nucleic Acids Res. 1983;11:2827-2837.
40. Nichols AV, Blanche PJ, Gong EL. Gradient gel electrophoresis of human plasma high density lipoproteins. In: Lewis LA, ed. Handbook of Electrophoresis. Boca Raton, Fla: CRC Press Inc; 1983;3:29-47.
41. 344→Ser). J Lipid Res. 1995;36:2329-2343.
42. Stokke KT, Norum KR. Determination of lecithin: cholesterol acyltransferase in human blood plasma. Scand J Clin Lab Invest. 1971;27:21-27.
43. Lacko AG, Rutenberg HL, Soloff LA. Recovery of labeled cholesterol and cholesterol esters from thin layer chromatograms. Clin Chim Acta. 1972;39:506-510.
44. Albers JJ, Adolphson JL, Chen CH. Radioimmunoassay of human lecithin: cholesterol acyltransferase. J Clin Invest. 1981;67:141-146.
45. Tollefson JH, Albers JJ. Isolation, characterization, and assay of plasma lipid transfer proteins. Methods Enzymol. 1986;129:797-816.
46. Gotoda T, Yamada N, Murase T, Sakuma M, Murayama N, Shimano H, Kanzaki K, Albers JJ, Yazaki Y, Akanuma Y. Differential phenotypic expression by three mutant alleles in familial lecithin: cholesterol acyltransferase deficiency. Lancet. 1991;338:778-781.
47. Klein HG, Lohse P, Pritchard PH, Bojanovski D, Schmidt H, Brewer HB Jr. Two different allelic mutations in the lecithin-cholesterol acyltransferase gene associated with fish eye syndrome. J Clin Invest. 1992;89:499-506.
48. 156→asn). J Lipid Res. 1993;34:49-58.
49. Schmidt HH-J, Remaley AT, Stonik JA, Roman R, Wellmann A, Thomas F, Zech LA, Brewer HB Jr, Hoeg JM. Carboxyl-terminal domain truncation alters apolipoprotein A-I in vivo catabolism. J Biol Chem. 1995;270:5469-5475.
50. Milano apoprotein. J Clin Invest. 1980;66:892-900.
51. Milano apoprotein. J Clin Invest. 1980;66:901-907.
52. Milano. J Biol Chem. 1983;258:2508-2513.
53. Milano variant. J Biol Chem. 1982;257:9926-9930.
54. Milano, a cause of high density lipoprotein deficiency. J Clin Res. 1982;30:393a. Abstract.
55. Norum KR, Gjone E, Glomset JA. Familial lecithin: cholesterol acyltransferase deficiency, including fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Vale D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill Publishing Co; 1989:1181-1194.
56. Subbaiah PV, Norum RA, Bagdade JD. Effect of apolipoprotein activators on the specificity of lecithin:cholesterol acyltransferase: determination of cholesteryl esters formed in A-I/C-III deficiency. J Lipid Res. 1991;32:1601-1609.